Related Experiment Video

Updated: Feb 20, 2026

Dynamic Imaging of Chimeric Antigen Receptor T Cells with [18F]Tetrafluoroborate Positron Emission Tomography/Computed Tomography
09:34

Dynamic Imaging of Chimeric Antigen Receptor T Cells with [18F]Tetrafluoroborate Positron Emission Tomography/Computed Tomography

Published on: February 17, 2022

3.9K

Long-term survival with lisocabtagene maraleucel in second-line large B-cell lymphoma from TRANSFORM

Manali Kamdar1, Scott R Solomon2, Jon E Arnason3

  • 1University of Colorado Cancer Center, Aurora, Colorado, United States.

Blood Advances
|February 18, 2026
PubMed
Abstract

No abstract available in PubMed .

More Related Videos

Author Spotlight: Assessing the Potential of Circulating Tumor Cells in Leptomeningeal Disease Research
06:25

Author Spotlight: Assessing the Potential of Circulating Tumor Cells in Leptomeningeal Disease Research

Published on: March 29, 2024

1.6K
A Nonviral Approach to Generate Transient Chimeric Antigen Receptor T Cells Using mRNA for Cancer Immunotherapy
09:56

A Nonviral Approach to Generate Transient Chimeric Antigen Receptor T Cells Using mRNA for Cancer Immunotherapy

Published on: February 21, 2025

1.4K

Related Experiment Videos

Last Updated: Feb 20, 2026

Dynamic Imaging of Chimeric Antigen Receptor T Cells with [18F]Tetrafluoroborate Positron Emission Tomography/Computed Tomography
09:34

Dynamic Imaging of Chimeric Antigen Receptor T Cells with [18F]Tetrafluoroborate Positron Emission Tomography/Computed Tomography

Published on: February 17, 2022

3.9K
Author Spotlight: Assessing the Potential of Circulating Tumor Cells in Leptomeningeal Disease Research
06:25

Author Spotlight: Assessing the Potential of Circulating Tumor Cells in Leptomeningeal Disease Research

Published on: March 29, 2024

1.6K
A Nonviral Approach to Generate Transient Chimeric Antigen Receptor T Cells Using mRNA for Cancer Immunotherapy
09:56

A Nonviral Approach to Generate Transient Chimeric Antigen Receptor T Cells Using mRNA for Cancer Immunotherapy

Published on: February 21, 2025

1.4K

Related Concept Videos

Treatment Resistant Cancers02:56

Treatment Resistant Cancers

3.8K
Cancer is the second leading cause of death in the United States. A cancer cell is genetically unstable and hence can mutate faster. They can also modify their microenvironment and escape immune surveillance. The difficulties in treating cancer are further compounded by the emergence of rapid resistance to anticancer drugs. The most common ways to attain resistance in cancer cells include alteration in drug transport and metabolism, modification of drug target, elevated DNA damage response, or...
3.8K
Targeted Cancer Therapies02:57

Targeted Cancer Therapies

9.0K
The targeted cancer therapies, also known as “molecular targeted therapies,” take advantage of the molecular and genetic differences between the cancer cells and the normal cells. It needs a thorough understanding of the cancer cells to develop drugs that can target specific molecular aspects that drive the growth, progression, and spread of cancer cells without affecting the growth and survival of other normal cells in the body.
There are several types of targeted therapies against...
9.0K

Articles linked to this work by shared authors, journal, and citation graph.

Summary of Research: Brentuximab Vedotin and Nivolumab in Combination with Chemotherapy for Nonbulky, Early-Stage Classical Hodgkin Lymphoma.

Advances in therapy·2026

Allogeneic stem cell transplantation after myeloablative conditioning with fludarabine, thiotepa, and cyclophosphamide in relapsed or refractory aggressive B-cell and T-cell lymphomas: results of the prospective ASTRAL study.

Haematologica·2026

Interindividual HLA evolutionary divergence in mismatched unrelated donor allo-HCT for malignant hematological disorders.

Blood advances·2026

Haematopoietic stem cell transplantation in hepatosplenic T-cell lymphoma: a retrospective analysis of the EBMT Lymphoma Working Party.

The Lancet. Haematology·2026

Case report: Eosinophilia as a rare symptom and primary sign of acute lymphoblastic leukemia with translocation (5;14)(q31;q32).

Frontiers in oncology·2026

Durable efficacy and manageable long-term safety of lisocabtagene maraleucel in 3L+ FL: 3-year update from TRANSCEND FL.

Blood·2026

Comprehensive genetic characterization of adult BCR::ABL1-negative B-ALL by Optical Genome Mapping and Targeted NGS.

Blood advances·2026

A machine learning-derived sarcopenia index is associated with survival and nonrelapse mortality in DLBCL.

Blood advances·2026

Molecular Profiling and Disease Tracking of Post-transplant Lymphoproliferative Disorders using Cell-free DNA.

Blood advances·2026

Chemotherapy-related anaemia is regulated through Caspase-1 mediated ROCK1 activation.

Blood advances·2026

Survival Improvement of DLBCL Patients Treated with Third Line and Beyond in the Recent Era in the Czech Republic.

Blood advances·2026

Patient-Reported Outcomes in Clinical Trials: Lessons from the Blood and Marrow Transplant Clinical Trials Network.

Blood advances·2026

Clinical Diagnosis and Treatment Analyses on Dedifferentiated Liposarcoma of the Head and Neck: A Single-Center Experience With Systematic Review of the Literature.

The Journal of craniofacial surgery·2026

[Single-center analysis of surgery and prognosis in 927 patients with hepatocellular carcinoma at CNLC stages Ⅰa to Ⅲa].

Zhonghua wai ke za zhi [Chinese journal of surgery]·2026

[The role and evaluation of ALPPS in surgical treatment of hepatocellular carcinoma in the era of conversion therapy].

Zhonghua wai ke za zhi [Chinese journal of surgery]·2026

[Clinical practice guideline for laparoscopic radical resection of intrahepatic cholangiocarcinoma(2026)].

Zhonghua wai ke za zhi [Chinese journal of surgery]·2026

Lipoprotein (a) Testing and Changes in Lipid-Lowering Therapy in Patients With ASCVD: Findings From the cvMOBIUS-2 Registry.

Circulation. Population health and outcomes·2026

When safe isn't safe together: co-exposure to individually sub-cytotoxic compounds alters functional integrity of HepG2-derived liver 3D spheroids.

Toxicology·2026
See all related articles
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies
Jove
Visualize
Contact Us